Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 8/20 | 0.56 |
| ▸ | S1PR5 | Q9H228 | 8/20 | 0.56 |
| ▸ | GPR52 | Q9Y2T5 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1856500 | 0.91 | GPR52 (0.66) | S1PR4S1PR5GPR52MEN1MAPT | |
| SCHEMBL1854277 | 0.88 | S1PR5 (0.63) | S1PR4S1PR5GPR52 | |
| SCHEMBL3198611 | 0.84 | GPR52 (0.76) | S1PR4S1PR5GPR52 | |
| SCHEMBL1848119 | 0.84 | GPR52 (0.71) | S1PR4S1PR5GPR52MEN1MAPT | |
| SCHEMBL1850704 | 0.84 | GPR52 (0.60) | S1PR4S1PR5GPR52MEN1MAPT | |
| SCHEMBL1849808 | 0.83 | GPR52 (0.53) | S1PR4S1PR5GPR52MEN1MAPT | |
| SCHEMBL3210261 | 0.82 | GPR52 (0.75) | S1PR4S1PR5GPR52MAPT | |
| SCHEMBL3208693 | 0.81 | GPR52 (0.51) | S1PR4S1PR5GPR52MEN1MAPT | |
| SCHEMBL1849090 | 0.80 | GPR52 (0.60) | S1PR4S1PR5GPR52MEN1MAPT | |
| SCHEMBL1848922 | 0.80 | GPR52 (0.46) | S1PR4S1PR5GPR52TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | S1PR4 565/4885S1PR5 696/4885GPR52 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.